1. Home
  2. MURA vs UBXG Comparison

MURA vs UBXG Comparison

Compare MURA & UBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • UBXG
  • Stock Information
  • Founded
  • MURA 2013
  • UBXG 2018
  • Country
  • MURA Ireland
  • UBXG China
  • Employees
  • MURA N/A
  • UBXG N/A
  • Industry
  • MURA
  • UBXG
  • Sector
  • MURA
  • UBXG
  • Exchange
  • MURA Nasdaq
  • UBXG Nasdaq
  • Market Cap
  • MURA 36.0M
  • UBXG 38.2M
  • IPO Year
  • MURA N/A
  • UBXG 2024
  • Fundamental
  • Price
  • MURA $2.08
  • UBXG N/A
  • Analyst Decision
  • MURA Buy
  • UBXG
  • Analyst Count
  • MURA 2
  • UBXG 0
  • Target Price
  • MURA $6.00
  • UBXG N/A
  • AVG Volume (30 Days)
  • MURA 157.1K
  • UBXG 721.5K
  • Earning Date
  • MURA 11-12-2025
  • UBXG 01-01-0001
  • Dividend Yield
  • MURA N/A
  • UBXG N/A
  • EPS Growth
  • MURA N/A
  • UBXG N/A
  • EPS
  • MURA N/A
  • UBXG N/A
  • Revenue
  • MURA N/A
  • UBXG $39,603,353.00
  • Revenue This Year
  • MURA N/A
  • UBXG N/A
  • Revenue Next Year
  • MURA N/A
  • UBXG N/A
  • P/E Ratio
  • MURA N/A
  • UBXG N/A
  • Revenue Growth
  • MURA N/A
  • UBXG N/A
  • 52 Week Low
  • MURA $0.95
  • UBXG $1.62
  • 52 Week High
  • MURA $4.74
  • UBXG $9.52
  • Technical
  • Relative Strength Index (RSI)
  • MURA 53.11
  • UBXG 35.32
  • Support Level
  • MURA $2.06
  • UBXG $1.76
  • Resistance Level
  • MURA $2.12
  • UBXG $1.94
  • Average True Range (ATR)
  • MURA 0.02
  • UBXG 0.19
  • MACD
  • MURA -0.00
  • UBXG 0.02
  • Stochastic Oscillator
  • MURA 41.67
  • UBXG 27.42

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About UBXG U-BX Technology Ltd. Ordinary Shares

U-BX Technology Ltd is focused on providing value-added services using artificial intelligence-driven technology to businesses within the insurance industry, including insurance carriers and brokers. It helps institutional clients obtain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or its clients' promotion time through those channels. The company derives a majority of its revenue by providing digital promotion services to its clients and also engages in providing risk assessment services, and value-added bundled benefits. It has developed an algorithm named Magic Mirror, to calculate payout risks for insurance carriers to underwrite auto insurance coverage. Geographically, all of the company's revenue is derived from Mainland China.

Share on Social Networks: